CTLA-4 Protects against Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Mice.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
30 05 2019
Historique:
received: 01 03 2019
accepted: 17 05 2019
entrez: 1 6 2019
pubmed: 31 5 2019
medline: 24 10 2020
Statut: epublish

Résumé

Vascular inflammation via T-cell-mediated immune responses has been shown to be critically involved in the pathogenesis of abdominal aortic aneurysm (AAA). T-cell coinhibitory molecule cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is known to act as a potent negative regulator of immune responses. However, the role of this molecule in the development of AAA remains completely unknown. We determined the effects of CTLA-4 overexpression on experimental AAA. We continuously infused CTLA-4 transgenic (CTLA-4-Tg)/apolipoprotein E-deficient (Apoe

Identifiants

pubmed: 31147569
doi: 10.1038/s41598-019-44523-6
pii: 10.1038/s41598-019-44523-6
pmc: PMC6542846
doi:

Substances chimiques

CTLA-4 Antigen 0
Ctla4 protein, mouse 0
Angiotensin II 11128-99-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8065

Références

Arterioscler Thromb Vasc Biol. 2017 May;37(5):764-777
pubmed: 28360089
J Am Heart Assoc. 2018 Jan 24;7(3):
pubmed: 29367417
Arterioscler Thromb Vasc Biol. 2017 Jan;37(1):66-74
pubmed: 27765767
Hypertension. 2015 Apr;65(4):889-95
pubmed: 25601931
Nat Med. 2006 Feb;12(2):178-80
pubmed: 16462800
Hypertension. 2014 Oct;64(4):875-82
pubmed: 25024283
Cell. 2008 May 30;133(5):775-87
pubmed: 18510923
Annu Rev Immunol. 2005;23:515-48
pubmed: 15771580
Arterioscler Thromb Vasc Biol. 2016 Jun;36(6):1141-51
pubmed: 27055906
Cardiovasc Res. 2014 Apr 1;102(1):107-17
pubmed: 24403315
Clin Rheumatol. 2016 Nov;35(11):2657-2661
pubmed: 27502778
Curr Pharm Des. 2015;21(9):1107-17
pubmed: 25312730
J Clin Invest. 2000 Jun;105(11):1605-12
pubmed: 10841519
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2605-13
pubmed: 16973970
Ann Rheum Dis. 2012 Sep;71(9):1524-9
pubmed: 22425941
Arterioscler Thromb Vasc Biol. 2013 Oct;33(10):2374-9
pubmed: 23908246
Eur J Immunol. 2005 Feb;35(2):399-407
pubmed: 15668914
Circ Res. 2015 Mar 13;116(6):1022-33
pubmed: 25767287
Cardiovasc Res. 2018 Mar 1;114(3):368-377
pubmed: 29309533
J Am Heart Assoc. 2017 Aug 31;6(9):
pubmed: 28860231
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Clin Invest. 2013 Mar;123(3):1323-34
pubmed: 23426179
Circulation. 2010 Dec 14;122(24):2529-37
pubmed: 21126972
Arterioscler Thromb Vasc Biol. 2015 Aug;35(8):1746-55
pubmed: 26044582
Circulation. 2009 Nov 17;120(20):1996-2005
pubmed: 19884470
Immunol Rev. 2011 May;241(1):180-205
pubmed: 21488898
Circulation. 2004 Apr 27;109(16):2009-15
pubmed: 15096453

Auteurs

Hilman Zulkifli Amin (HZ)

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.
Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

Naoto Sasaki (N)

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. n-sasaki@kobepharma-u.ac.jp.
Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan. n-sasaki@kobepharma-u.ac.jp.

Tomoya Yamashita (T)

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Taiji Mizoguchi (T)

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.

Tomohiro Hayashi (T)

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Takuo Emoto (T)

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Takuya Matsumoto (T)

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Naofumi Yoshida (N)

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Tokiko Tabata (T)

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Sayo Horibe (S)

Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.

Shoji Kawauchi (S)

Education and Research Center for Clinical Pharmacy, Kobe Pharmaceutical University, Kobe, Japan.

Yoshiyuki Rikitake (Y)

Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.

Ken-Ichi Hirata (KI)

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH